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Abstract
Background: Palliative thoracic radiotherapy is an effective technique to alleviate symptoms of disease burden in
advanced-stage lung cancer patients. Previous randomized controlled studies demonstrated a survival benefit in
patients with good performance status at radiation doses of 35Gy10 or greater but with an increased incidence of
esophagitis. The objective of this planning study was to assess the potential impact of esophageal-sparing IMRT
(ES-IMRT) compared to the current standard of care using parallel-opposed pair beams (POP).
Methods: In this study, 15 patients with lung cancer treated to a dose of 30Gy in 10 fractions between August
2015 and January 2016 were identified. Radiation treatment plans were optimized using ES-IMRT by limiting the
max esophagus point dose to 24Gy. Using published Lyman-Kutcher-Burman normal tissue complication
probabilities (LKB-NTCP) models, both plans were evaluated for the likelihood of esophagitis (≥ grade 2) and
pneumonitis (≥ grade 2).
Results: Using ES-IMRT, the median esophageal and lung mean doses reduced from 16 and 8Gy to 7 and 7Gy,
respectively. Using the LKB models, the theoretical probability of symptomatic esophagitis and pneumonitis reduced
from 13 to 2%, and from 5 to 3%, respectively. The median normalize total dose (NTD mean) accounting for fraction
size for the GTV and PTV of the clinically approved POP plans compared to the ES-IMRT plans were similar.
Conclusion: Advanced radiotherapy techniques such as ES-IMRT may have clinical utility in reducing treatment-related
toxicity in advanced lung cancer patients. Our data suggests that the rate of esophagitis can be reduced without
compromising local control.
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Background
Palliative radiotherapy can be an effective modality to
alleviate and prevent symptoms related to advanced stage
non-small cell lung cancer (NSCLC). In this setting, a
meta-analysis of randomized controlled trials (RCTs) con-
cluded that higher palliative radiation doses (specifically,
exceeding a dose of 35 Gy10) were associated with a
modest improvement in overall survival, but at the cost of
increased rates of dysphagia [1]. These RCTs were con-
ducted in an era where radiation delivery for these
patients was limited to simple beam arrangements, e.g. a
parallel-opposed pair (POP).
Since then, there have been a number of advances in ra-
diation planning and delivery, such as intensity modulated
radiotherapy (IMRT), which has been widely adopted and
implemented in the curative setting for a number of treat-
ment sites where normal tissue toxicity may present a lim-
iting factor such as in head and neck cancers, for example
[2]. IMRT permits a more conformal radiation dose
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through treatment planning optimization and field modu-
lation but is needs greater resources, time, and costs.
While IMRT is not routinely used in the palliative lung
radiotherapy setting, it could be employed to minimize
dose to the esophagus, which would typically receive the
full treatment dose in a POP beam arrangement delivered
in the common scenario of centrally located lung cancer
and/or bulky mediastinal lymphadenopathy causing symp-
toms. A recent study described and reported the clinical
IMRT treatment approach in 20 curative-intent NSCLC
patients whereby the contralateral esophagus wall was
spared without compromising planning target volume
(PTV) coverage with favourable results [3].
Under the auspices of the Canadian Pulmonary
Radiotherapy Group (CAPRI, http://www.capriclinical
trials.com/), patients with advanced-stage NSCLC pa-
tients are being recruited to a randomized phase III
trial, PROACTIVE (NCT02752126), comparing palliative
POP radiotherapy versus esophageal-sparing IMRT
(ES-IMRT). As the use of ES-IMRT in PROACTIVE
has implications of underdosing of PTV and increased
dose to other organs at risk (OARs), the purpose of this
planning study is to assess the feasibility of esophageal-
sparing IMRT (ES-IMRT), and the potential benefits of
ES-IMRT compared to the current standard of treatment.
Methods
In this institutional research ethics board-approved study
(Western University, REB ID: 107547) patients with ad-
vanced lung cancer treated with standard palliative radio-
therapy (30 Gy in 10 fractions) between August 2015 and
January 2016 were identified. Patients were eligible for
study inclusion if the standard-of-care POP patient plans
contained at least 5 cm of the esophagus within the treat-
ment field. The standard approach for palliative planning
employs a fast helical scan with a 5 mm CTV isotropic ex-
pansion for microscopic disease and a 5 mm PTV margin.
As the final decision of treatment intent was unclear at
the time of their CT simulation scan a small number of
patients had a 4DCT performed. In this situation the ITV
was expanded by 10 mm or more (chosen expansion at
the discretion of the treating oncologist) to form the PTV.
In either situation, the GTV or ITV was examined or
modified to ensure no overlap with the defined (normal)
esophagus contour. The field borders in either simulation
situation were at least 5 mm away from the PTV accord-
ing to the digitally reproduced radiograph. Multi-leaf colli-
mators were used to shield organs-at-risk (OAR), which
included, the heart, healthy lung (defined as left and right
lung minus GTV), and cord.
A separate optimized esophageal-sparing (ES-IMRT)
treatment was created using a Volumetric Modulated
Arc Therapy (VMAT) approach with the goal of limiting
the max esophagus point dose to 80% of the prescription
(i.e. 24 Gy). To encourage a dose falloff for tumors that
were near or abutting the esophagus, a 5-mm ring was
created around the esophagus as an optimization struc-
ture. For portions of the PTV that overlapped with the
esophagus and esophagus ring, the PTV coverage was
compromised to allow a minimum of 20 Gy and the
remaining planning target volume the ESPTV was used
as a standard optimizing structure.
The dose to 95% of the volume (D95) contained within
ESPTV was required to be equal or better than the D95
of the PTV in the clinically delivered POP. If any portion
of the GTV was within this ring, the coverage was com-
promised such that no more than 1 cubic centimetre
dose could receive lower than 80% of the intended pre-
scription. To prevent dose from spilling into the healthy
lung (defined as left and right lung minus the GTV), the
volumes receiving 5 and 16 Gy (i.e.V5, and V16) of the
lung were required to be less than 60 and 35%, respect-
ively. No contiguous 2 cc volume was allowed to exceed
115% of the prescribed 30 Gy in either plan. Treatment
was calculated over one or two arcs with a collimator rota-
tions ranging between 10 and 45° and 315 to 350° using
Pinnacle 9.10 (Philips, Eindhoven, The Netherlands).
Competing treatment plans were evaluated using pub-
lished Lyman-Kutcher-Burman normal tissue complica-
tion probabilities (LKB-NTCP) models [4]. As there are
a number of publically available LBK-NTCP models, we
choose the two models that closely represented our
treatment (e.g. without concurrent chemotherapy), pa-
tient cohort, and primary endpoints of esophagitis (≥
grade 2, RTOG) [5] and pneumonitis (≥ grade 2, RTOG)
[6]. The input parameters for the LKB models were
TD50 = 44.9, n = 0.34, m = 0.34 and TD50 = 29.9, n = 1,
m = 0.41 for esophagitis and pneumonitis, respectively.
Earlier LKB-models with different parameters for
esophagitis by Belderbos et al. [7] and Chapet et al. [8]
were evaluated for completeness. The NTCP model was
calculated as outlined by Mohan et al. accounting for


























whereby m and n are the measure of the sigmoid slope
and volume effect, respectively. TD50 is the uniform
dose to an organ that results in a 50% complication rate
and vi is the fractional organ volume receiving a dose Di
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with the equivalent dose given in 2 Gy fractions. Separ-
ately, a sensitivity analysis was performed to determine
the impact of small changes to the treatment design.
The normalized total dose was used to estimate the









where, n, vi, and di represent the number of fractions
(i.e. 10), the fractional volume i receiving a discretized
dose at I, respectively. The alpha-beta ratio (α/β) used in
the NTD calculation was 10, while an α/β of 3 was used
for all normal tissue calculations. Dose volume histo-
grams were exported and read using Matlab (R2012b,
Mathworks, MA) where dosimetric parameters such as
the mean dose to the esophagus and lung were deter-
mined. Comparisons were made using the Wilcoxon
matched pair signed rank test. All statistical analyses
were performed using SAS software (versions 9.3, SAS
institute, CARY, USA), using two-sided statistical testing
at the 0.05 significance level.
Results
A total of 15 patients met the inclusion criteria. The
mean GTV and PTV volumes were 97.6 cc [22.3–
199.8] and 334.8 cc [164.1–564.9], respectively. Most
cases (n = 12) had a GTV directly abutting the esopha-
gus; all but one patient had a compromised PTV. The
average field size of the POP plan was 178 ± 67 cm2,
while the average length of the esophagus contained
within the field (D50) was 12 ± 3 cm.
Using ES-IMRT, the cohort mean esophageal dose was
reduced from 16 Gy to 8 Gy (p-value < 0.001). Reductions
in cohort mean lung dose from 8 Gy to 7 Gy were not sta-
tistically significant (p = 0.229). A representative example
of the two competing plans in one patient can be seen in
Fig. 1. The average and standard deviation of the cumula-
tive dose-volume plots for the GTV, PTV, esophagus, and
healthy lung for all the completing plans are shown in
Fig. 2. The difference in the average GTV D95 between
treatment arms was within 1%; however, the difference
of the average PTV D95 was 8% lower in the ES-IMRT
arm. Dose-volume metrics based on the plots in Fig. 2
are tabulated in Table 1.
Based on published LBK-NTCP models and the 15 pa-
tients studied herein, the mean probability of symptom-
atic esophagitis and pneumonitis reduced from 13 to 2%,
and from 5 to 3%, respectively, when using ES-IMRT.
Differences in mean predicted rates of toxicity for the
competing plans were found to be statistically significant
for both esophagitis (p-value < 0.001) and pneumonitis
(p-value = 0.005). Earlier LKB-models of esophagitis by
Belderbos et al. and Chapet et al. produced toxicity rates
of 7% and 6% for the POP arm, which equally reduced
to 1% in the ES-IMRT, suggesting that although the
absolute rates of toxicity may vary using fit parameters
derived from different insitutions, the relative reduction
in the rates of observed toxicity are similar when invok-
ing an esophagus-sparing strategy and LKB models.
The mean NTD for the GTV and PTV of the clinically
approved POP plan versus the ES-IMRT plans were 34.0
± 1.5 Gy and 33.7 ± 1.3 Gy, versus 34.3 ± 0.9 Gy and 33.3
± 0.8 Gy, and were not found to be found statistically dif-
ferent (p-value = 0.277) and (p-value = 0.847), respectively.
Discussion
Advanced radiotherapy techniques such as ES-IMRT
may have clinical utility in reducing treatment-related
toxicity in patients with advanced lung cancer. This
study suggests that when considering a dose of 30 Gy in
10 fractions, the rate of esophagitis may be reduced from
13 to 2%, while maintaining a similar normalized total
dose to the PTV. The lower calculated toxicity is a con-
sequence of reducing the dose to the esophagus through
the use of a ring structure that limited the maximum
dose near the esophagus, as well as a minimum dose
when the PTV overlapped with the ring structure, which
occurred for all but one of the patients. Although, the
earlier LKB-NTCP models by Belderbos et al. and Chapet
et al. resulted in lower absolute toxicities using parallel
Fig. 1 Axial and coronal CT slices illustrating the isodose distributions of
the competing POP and ES-IMRT plans. The blue contour shows the PTV
and overlap region (indicated by a red arrow) of the esophagus and
esophagus ring having a green overlay and green contour, respectively.
The turquoise colour overlay represents the uncompromised PTV
(the ESPTV)
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opposed fields the relative reduction using ES-IMRT
for all three evaluted NTCP models was similar be-
tween 5 and 7 times lower. The impact of the minimum
dose to the PTV of 20 Gy on the treatment planning
raised the likelihood of esophagitis from 1 to 2% as
reported. This incremental level of the probability of
esophagitis was felt to be a reasonable tolerance in
order to maintain coverage.
A partial dose reduction to the overlap region of the
esophagus and PTV in curative-intent patients is controver-
sial but has been recently proposed; and, based on these
reports, biological models suggest a meaningful reduction
in the likelihood of esophagitis without a compromise in
tumor control [9, 10].
Considering that the clinical objective for the patients
under investigation in this study is symptom relief over
local control, we believe that this cohort of patients
represents an interesting group from which to evaluate
the impact of partial PTV and GTV compromises. In
particular, patients treated with a compromised PTV
may reveal meaningful changes in quality of life that
would not have otherwise been recorded as a grade II
toxicity requiring medical intervention. Quite promis-
ingly, in a contralateral esophageal-sparing technique, 20
curative-intent patients experienced no grade 3 adverse,
4 patients recorded a grade 2 adverse event, and 11 pa-
tients recorded a grade 1 adverse event [3]. Given the
limited sample size and follow-up in this cohort, further
research is required to assess whether such a strategy is
generalizable and/or feasible in the broader patient
population.
Dysphagia induced as a result of esophagitis can cause
significant discomfort to the patient, and even place add-
itional stress on caregivers to ensure adequate nutrition is
being administered. Dysphagia has a multifactorial etiology
and differences exist in its assessment rating between
patient reported difficulty versus clinician ascribed [11].
Regardless, for curative-intent patients dysphagia has been
associated with inferior outcomes; therefore, strategies
to help mitigate radiation-induced associate esophagitis
through IMRT may improve the efficacy of treatment
and overall quality of life.
Conclusion
In conclusion, ES-IMRT may be useful in reducing dys-
phagia, but clinical data are needed to confirm the model-
Fig. 2 Average cumulative dose-volume line plots of the GTV (red), PTV (blue), esophagus (green), and lung (black) are shown for the clinically
delivered POP plans (solid line) compared to the ES-IMRT optimized plans (dashed line) for the 15 patients meeting the inclusion criteria. The
shaded envelope surrounding each line plot represents one standard deviation
Table 1 Dosimetric parameters describing the differences
between the standard parallel-opposed pair beam arrangement
vs. the proposed esophageal-sparing ES-IMRT plans
Parameter Parallel-opposed pair plan ES-IMRT esophagus sparing plan
D99 (GTV) 28.0 ± 1.0 Gy 24.7 ± 1.4 Gy
D95 (GTV) 28.9 ± 8.8 Gy 28.8 ± 4.8 Gy
D5 (GTV) 34.0 ± 14 Gy 32.9 ± 7.4 Gy
D99 (PTV) 26.5 ± 2.5 Gy 22.0 ± 0.8 Gy
D95 (PTV) 28.1 ± 4.6 Gy 25.9 ± 3.6 Gy
D5 (PTV) 33.8 ± 12 Gy 32.7 ± 4.4 Gy
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predicted benefits reported herein. Our data have formed
the basis for the design of a randomized phase III study of
Palliative Radiation of Advanced Central lung Tumors
with Intentional avoidance of the Esophagus (PRO-
ACTIVE), which is actively accruing patients with the goal
of assessing the clinical benefit of ES-IMRT.
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